Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies

Trial Profile

Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2018

At a glance

  • Drugs Anetumab ravtansine (Primary) ; Cisplatin; Gemcitabine
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ARCS-Multi
  • Sponsors Bayer
  • Most Recent Events

    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 23 May 2018 Planned End Date changed from 11 Feb 2020 to 29 Jan 2021.
    • 23 May 2018 Planned primary completion date changed from 31 May 2019 to 28 Feb 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top